Wednesday, 23 May 2018

Natco in focus ahead of Q4 numbers, to benefit from delay in Dr. Reddy’s gCopaxone

The delay in Dr. Reddy's gCopaxone will benefit Natco as it launched the drug in October 2017 and has only one generic competitor in this product category. Natco Pharma gained 5% in the opening hour trades today on the back of news that Dr. Reddy’s gCopaxone will get delayed further (read Dr. Reddy's Q4 result and concall notes). This leaves the gCopaxone competition limited to only two players i.e. Sandoz and Natco’s partner Mylan.

To Get Free Trial 
Missed call @ 9582541010 
Call Us @ 8822117117 
Mail Us = 
Visit =

No comments:

Post a Comment